Dear,
I am Sandrine Le Guellec, from Tours (france). I am study engineer and I work in the field of aerosoltherapy, new inhaled therapies, lung and nasal delivery, within Aerodrug department (DTF medical in collaboration with the CEPR U-1100 center of respiratory diseases (French Institut for medical research).
Do you think that a local administration of Dupilumab may be relevant to improve benefit risk balance ? This question is about nasal administration.
Thank you very much for your attention,
Sandrine
I'm not sure if monoclonal antibodies would absorb across epithelium, due to their size. Also, risks are already minimal within systemic administration (conjunctivitis).
I doubt that it would work and here in the U.S. the cost for allergic rhinitis would be prohibitive
Thanks
Dupilumab is an interleukin-4 receptor (IL-4Rα) antagonist through blockade of IL-4Rα.It modulates signaling of both the interleukin 4 and interleukin 13 pathways hence decreases the levels of Th2 bio-markers.
Since allergic disorders, almost alway are not local disorders but are considered as potentially occuring in any arogan, and if symptoms are present dominantly in one organ the other ones are in a ready to fire state, thus systemic effect of this expensive medication is more ideal and logic but not topical use of it.
At the other hand it is not evident yhe extent and durability of dupilumab when used topically.
best regards.
- Badges
- Science method